ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immunoglobulins, Intravenous

Also written as “NPB-01”, “TAK-881” and “IVIG”.

Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.

Drug pageImmunoglobulins, Intravenous: every studyMany companies study it; this page follows only the 83 they lead. All 227 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 12, 201783 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only203 open or runningphase 4since Apr 12, 2017Sep 8, 2005May 16, 2028phase 3 · NCT06076642
Grifols172 open or runningphase 4since Oct 24, 2011Sep 13, 2005Dec 31, 2027phase 3 · NCT07540221
Nihon Pharmaceuticalits history only80 open or runningphase 3since Jul 27, 2011Dec 11, 2008none ahead
Octapharmaits history only61 open or runningphase 3since Nov 11, 2009Nov 11, 2009Nov 2026phase 3 · NCT04640142
CSLits history only51 open or runningphase 3since Oct 12, 2011Oct 12, 2011May 6, 2029phase 2 · NCT07048262
Kedrionits history only53 open or runningphase 3since Apr 16, 2012Apr 16, 2012Dec 2026phase 3 · NCT07059000
Japan Blood Products Organizationits history only40 open or runningphase 3since Jun 8, 2006Jun 8, 2006none ahead
GC Biopharmaits history only31 open or runningphase 3since Jul 26, 2011Jul 26, 2011none ahead
Prothya Biosolutionsits history only30 open or runningphase 4since Aug 29, 2007Aug 29, 2007none ahead
Azidus Brasilits history only22 open or runningphase 3since Sep 19, 2023Sep 19, 2023Sep 2028phase 3 · NCT06150833

Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Grifols only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First studies: 3 phase 2 studiesFirst studyNCT00220779, NCT00220727, NCT00220805
  2. Sep 13, 20052 phase 3 studiesNCT00220766, NCT00220740
  3. Oct 17, 2006Phase 2 study in Immunologic Deficiency SyndromesNCT00389324 · 35 enrolled · United States, Canada
  4. Aug 1, 2007Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT00511147 · 64 enrolled · United States, Canada, India and more
  5. Jun 16, 2008Phase 3 study in Purpura, ThrombocytopenicNCT00699140 · 18 enrolled · Russian Federation, Spain, United Kingdom
  6. Oct 24, 2011Phase 4 study in Primary Immunodeficiency DiseasesNCT01465958 · 12 enrolled · United States
  7. Jun 25, 2014Phase 3 study in Postpoliomyelitis SyndromeNCT02176863 · 191 enrolled · United States, Canada, Czechia and more
  8. Apr 7, 2015Phase 3 study in Myasthenia Gravis ExacerbationsNCT02413580 · 49 enrolled · Argentina, Belgium, Canada and more
  9. Jun 14, 20152 phase 2 studies in Myasthenia GravisNCT02473965, NCT02473952
  10. Nov 20, 2017Phase 4 study in Anti-Hepatitis A Antibody Levels in Heathy SubjectsNCT03351933 · 28 enrolled · United States
  11. Jun 12, 2020Phase 2 study in COVID-19NCT04432324 · 100 enrolled · Spain
  12. Apr 9, 20262 phase 3 studiesNCT07540221, NCT07582432

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07540221
  2. Aug 31, 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07582432

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 Grifols leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07582432Leukemia, Lymphocytic, Chronic, B-Cell · United States3RecruitingAug 31, 202849
NCT07540221Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Czechia, Poland and more3RecruitingDec 31, 202740
NCT04432324COVID-19 · Spain2CompletedMar 3, 2021100
NCT03351933Anti-Hepatitis A Antibody Levels in Heathy Subjects · United States4CompletedApr 27, 201828
NCT02473965Myasthenia Gravis · United States, Belgium, Canada and more2CompletedFeb 201960
NCT02473952Myasthenia Gravis · United States, Belgium, Canada and more2CompletedJan 201862
NCT02413580Myasthenia Gravis Exacerbations · Argentina, Belgium, Canada and more3CompletedApr 201849
NCT02176863Postpoliomyelitis Syndrome · United States, Canada, Czechia and more3TerminatedNov 24, 2022191
NCT01465958Primary Immunodeficiency Diseases · United States4CompletedOct 201312
NCT00699140Purpura, Thrombocytopenic · Russian Federation, Spain, United Kingdom3CompletedDec 201318
NCT00511147Purpura, Thrombocytopenic, Idiopathic · United States, Canada, India and more3CompletedApr 201464
NCT00389324Immunologic Deficiency Syndromes · United States, Canada2CompletedAug 200835
NCT00220805Macular Degeneration · Germany2CompletedMay 200596
NCT00220779Multiple Sclerosis, Relapsing-Remitting · United States, Austria, Canada and more2CompletedFeb 2005128
NCT00220766Immunologic Deficiency Syndromes · United States, Canada3CompletedAug 2002100
NCT00220740Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Canada and more3CompletedJun 2006117
NCT00220727Purpura, Thrombocytopenic, Idiopathic · United States2CompletedOct 20038

How it is read

Names in the registry

  • “NPB-01”, 7 entries
  • “TAK-881”, 6 entries
  • “IVIG”, 6 entries
  • “Kedrion IVIG 10%”, 4 entries
  • “GB-0998”, 4 entries

Codes read as this program: TAK881, GC5107, GB0998.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.